Citigroup Issues Pessimistic Forecast for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price

Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its price target cut by investment analysts at Citigroup from $35.00 to $17.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Citigroup’s price objective would indicate a potential upside of 216.10% from the stock’s current price.

Several other analysts also recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Friday, July 17th. HC Wainwright reissued a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research report on Tuesday. Cantor Fitzgerald lowered shares of Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a report on Monday. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research report on Monday. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $5.00 target price on shares of Eyepoint Pharmaceuticals in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Eyepoint Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $28.11.

Eyepoint Pharmaceuticals Stock Performance

EYPT stock traded up $0.51 during midday trading on Tuesday, hitting $5.38. 9,446,036 shares of the company’s stock were exchanged, compared to its average volume of 1,677,884. The stock’s fifty day moving average price is $13.10 and its 200-day moving average price is $13.62. The company has a market cap of $463.64 million, a PE ratio of -1.43 and a beta of 1.76. Eyepoint Pharmaceuticals has a one year low of $3.95 and a one year high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%.The business had revenue of $0.51 million during the quarter, compared to the consensus estimate of $0.45 million. On average, analysts expect that Eyepoint Pharmaceuticals will post -3.6 EPS for the current year.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EYPT. KBC Group NV acquired a new position in shares of Eyepoint Pharmaceuticals during the 1st quarter worth about $29,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Eyepoint Pharmaceuticals by 51.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock worth $74,000 after acquiring an additional 1,358 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in Eyepoint Pharmaceuticals during the third quarter worth about $76,000. Tower Research Capital LLC TRC grew its stake in Eyepoint Pharmaceuticals by 218.3% in the second quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock valued at $82,000 after purchasing an additional 5,967 shares in the last quarter. Finally, California State Teachers Retirement System increased its position in shares of Eyepoint Pharmaceuticals by 20.6% during the 4th quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock worth $85,000 after purchasing an additional 794 shares during the last quarter. 99.41% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: DURAVYU was reported as non-inferior to aflibercept in an ad hoc analysis that excluded an asymmetric group of nine patients whose vision loss was considered unrelated to wet AMD. The company also highlighted a 42% reduction in treatment burden, favorable safety with redosing, strong anatomic control, and other supportive secondary endpoints. EyePoint LUGANO trial results
• Positive Sentiment: Jefferies maintained a “buy” rating while lowering its price target to $8, implying substantial upside from recent trading levels. Chardan also previously maintained a bullish rating, although its latest view has changed.
• Neutral Sentiment: Trading in EYPT was temporarily halted for pending news before the clinical-trial results were released, reflecting the market significance of the announcement.
• Neutral Sentiment: HC Wainwright reaffirmed its “neutral” rating, while JPMorgan reaffirmed its neutral view. Chardan Capital and RBC also reaffirmed neutral or sector-perform ratings, each assigning a $5 price target.
• Negative Sentiment: The full LUGANO dataset did not achieve the trial’s primary endpoint, a major setback for DURAVYU’s regulatory and commercial prospects. The company may need to explain the impact of the vision-loss cohort and how the remaining Phase 3 program will proceed. Reuters EyePoint trial report
• Negative Sentiment: Cantor Fitzgerald downgraded EyePoint from “overweight” to “neutral,” while multiple analysts have reduced or reaffirmed cautious price targets. Investor discussion has also shifted toward competing ophthalmology companies as potentially stronger opportunities.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.